Adalimumab-Adbm(Cf) Pen (Adalimumab-Adbm) Patent Expiration, LOE Window & CMS Spending

Adalimumab-Adbm(Cf) Pen (Adalimumab-Adbm) by Boehringer Ingelheim: Off-Patent Genericized (AB Competition), 0 AB generics, $320K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$320K
2024 Medicare Part D Spend$143K
2024 Medicaid Spend$177K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.